切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2017, Vol. 11 ›› Issue (17) : 2163 -2166. doi: 10.3877/cma.j.issn.1674-0785.2017.17.001

所属专题: 文献

临床论著

急性脑梗死不同剂量阿替普酶静脉溶栓安全性分析
周生奎1,(), 刘雷婧1, 刘薇薇1, 平蕾1, 陈国芳1   
  1. 1. 221009 徐州市中心医院神经内科
  • 收稿日期:2017-04-10 出版日期:2017-09-01
  • 通信作者: 周生奎

Safety of different doses of alteplase for intravenous thrombolysis in patients with acute cerebral infarction

Shengkui Zhou1,(), Leijing Liu1, Weiwei Liu1, Lei Ping1, Guofang Chen1   

  1. 1. Department of Neurology, Central Hospital of Xuzhou City, Xuzhou 221009, China
  • Received:2017-04-10 Published:2017-09-01
  • Corresponding author: Shengkui Zhou
  • About author:
    Corresponding author: Zhou Shengkui, Email:
引用本文:

周生奎, 刘雷婧, 刘薇薇, 平蕾, 陈国芳. 急性脑梗死不同剂量阿替普酶静脉溶栓安全性分析[J]. 中华临床医师杂志(电子版), 2017, 11(17): 2163-2166.

Shengkui Zhou, Leijing Liu, Weiwei Liu, Lei Ping, Guofang Chen. Safety of different doses of alteplase for intravenous thrombolysis in patients with acute cerebral infarction[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(17): 2163-2166.

目的

比较不同剂量阿替普酶静脉溶栓的安全性,为临床合理用药提供依据。

方法

选取2012年3月至2015年8月期间在徐州市中心医院神经内科接受静脉阿替普酶溶栓治疗的急性脑梗死患者283例随机分为2组,低剂量组140例,标准剂量组143例,采集所有患者的病历资料,以改良Rankin量表评分0~2分为预后良好,采用卡方检验或者Mann-Whitney U检验比较2组患者临床疗效及病死率,评估急性脑梗死不同剂量阿替普酶静脉溶栓的安全性。

结果

(1)2组患者在溶栓24 h、3 d的美国国立卫生研究院卒中量表(NIHSS评分)相比,差异无统计学意义[6(2,12) vs 5(2,10),U=0.361,P=0.718;4(2,11) vs 4(2,10),U=0.118,P=0.906];溶栓后7、28、90 d,2组预后良好率比较差异无统计学意义(52.86% vs 53.85%,χ2=0.002,P=0.962;64.29% vs 62.94%,χ2=0.013,P=0.911;70.00% vs 72.03%,χ2=0.06,P=0.807)。(2)2组患者溶栓后出血转化率无明显差异(6.43% vs 7.69%,χ2=0.040,P=0.842),溶栓后90 d内低剂量组死亡11例,标准剂量组死亡12例,2组死亡率无明显差异(χ2=0.120,P=0.73)。

结论

不同剂量阿替普酶静脉溶栓治疗急性脑梗死安全性和疗效相似,低剂量阿替普酶静脉溶栓值得临床推广应用。

Objective

To compare the safety of different doses of alteplase for intravenous thrombolysis in patients with acute cerebral infarction to provide a basis for clinical rational use of this drug.

Methods

A total of 283 acute cerebral infarction patients were randomly divided into a low dose group (n=140) and a standard dose group (n=143). The medical records of all patients were collected, and the prognosis of patients was evaluated with the modified Rankin scale (mRS), with an mRS score of 0-2 indicating a good prognosis. The chi-square test or Mann-Whitney U test was used to compare the clinical efficacy and mortality of the two groups, and to evaluate the safety of different doses of alteplase for intravenous thrombolysis in patients with acute cerebral infarction.

Results

At 24 h and 3 days after thrombolysis, there was no significant difference in the National Institute of Health stroke scale (NIHSS) between the two groups [6 (2, 12) vs 5 (2, 10), Z=0.361, P=0.718; 4 (2, 11) vs 4 (2, 10), Z=0.118, P=0.906]. At 7, 28, and 90 d after thrombolysis, there was no significant difference in the proportion of patients with a good prognosis between the two groups (52.86% vs 53.85%, χ2=0.002, P=0.962; 64.29% vs 62.94%, χ2=0.013, P=0.911; 70.00% vs 72.03%, χ2=0.06, P=0.807). There was no significant difference in the rate of hemorrhagic transformation between the two groups after thrombolysis (6.43% vs 7.69%, χ2=0.040, P=0.842). By 90 days after thrombolysis, 11 patients in the low dose group and 12 patients in the standard dose group died, and there was no significant difference in mortality between the two groups (χ2=0.120, P=0.73).

Conclusion

Different doses of alteplase for intravenous thrombolysis in patients with acute cerebral infarction have similar safety and efficacy, and low doses of alteplase for intravenous thrombolysis is worthy of clinical application.

表1 2组急性脑梗死患者临床资料比较
表2 不同剂量阿替普酶静脉溶栓安全性及预后比较
[1]
Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview [J]. CircRes, 2017, 120(3): 541-558.
[2]
张锦丽, 闫敏, 王璐琰. 不同剂量阿替普酶溶栓治疗急性脑梗死效果评价 [J]. 解放军医药杂志, 2014, 26(11): 79-81.
[3]
Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke [J]. N Engl J Med, 2016, 374(24): 2313-2323.
[4]
中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014 [J]. 中华神经科杂志, 2015, 48(4): 258-268.
[5]
Living AOD. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. [J]. N Engl J Med, 1995, 333(24): 1581-1587.
[6]
Lees KR, Emberson J, Blackwell L, et al. Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials [J]. Stroke, 2016, 47(9): 2373.
[7]
Morihara R, Kono S, Sato K, et al. Thrombolysis with low-dose tissue plasminogen activator 3-4.5 h after acute ischemic stroke in five hospital groups in Japan [J]. Transl Stroke Res, 2016, 40(2): 1-9.
[8]
Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous Alteplase in acute ischemic stroke [J]. N Engl J Med, 2016, 374(24): 2313-2323.
[9]
Kim BJ, Han MK, Park TH, et al. Low-versus standard-dose Alteplase for ischemic strokes within 4. 5 hours: a comparative effectiveness and safety study [J]. Stroke, 2015, 46(9): 2541-2548.
[10]
Chao AC, Hsu HY, Chung CP, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke(TTT-AIS) study [J]. Stroke, 2010, 41(5): 885-890.
[11]
廖晓凌, 王伊龙, 潘岳松, 等. 急性缺血性卒中不同剂量阿替普酶静脉溶栓疗效比较 [J]. 中国卒中杂志, 2014, 9(7): 551-556.
[12]
张生, 张秋莲, 甄志刚, 等. 基层医院阿替普酶静脉溶栓治疗急性缺血性脑卒中117例疗效分析 [J]. 中华老年心脑血管病杂志, 2016, 18(11): 1186-1190.
[13]
Zhou XY, Wang SM, Davis SM, et al. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke [J]. J Clin Neurosci, 2011, 18(1): 988-992.
[1] 程飞, 杨辉, 周世玲, 赵航. 静脉溶栓后机械取栓桥接治疗急性大动脉闭塞脑梗死可行性研究[J]. 中华神经创伤外科电子杂志, 2023, 09(03): 149-153.
[2] 马丽. CT灌注联合血管成像预测急性脑梗死患者近期神经功能预后的价值分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 229-234.
[3] 许秀兰, 朱建建. 血压变异性与伴H型高血压的急性脑梗死患者预后不良的临床关系分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 199-204.
[4] 林影, 李建红, 卢宏全, 陈俊玲. 急性脑梗死患者血清正五聚蛋白3水平与其血脂、认知功能及预后的关系研究[J]. 中华临床医师杂志(电子版), 2022, 16(05): 420-424.
[5] 季鹏, 郭言言, 王超. CT灌注成像联合CT血管造影对TIA患者进展为急性脑梗死的预测[J]. 中华介入放射学电子杂志, 2023, 11(02): 128-132.
[6] 朱敏, 李法强. 血清GFAP、UCH-L1联合VILIP-1水平对急性脑梗死神经功能预后不良的预测研究[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 452-457.
[7] 李昕, 李永凯, 江树青, 夏来百提姑·赛买提, 杨建中. 急性缺血性脑卒中静脉溶栓后出血转化相关危险因素分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 331-336.
[8] 王晖, 张淑娟, 周宝华, 杨琼, 罗永梅. 基于卒中单元的缺血性脑卒中静脉溶栓模式的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 150-153.
[9] 俞刘珍雄, 张康睿, 杨若蕊, 刘学春, 王龙, 吴竹青, 吴君仓. 维生素D水平与接受静脉溶栓治疗的缺血性卒中患者预后的关系[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 94-101.
[10] 饶伟, 曹文锋, 项正兵, 刘世民, 周勇良, 文安, 吴凌峰. 丁苯酞氯化钠注射液在急性脑梗死静脉溶栓治疗中的应用研究[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 89-93.
[11] 张运, 裴月红, 傅瑜. 急性缺血性卒中静脉溶栓治疗进展[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 83-88.
[12] 李昕, 杨建中. 急性缺血性脑卒中静脉溶栓后出血转化危险因素的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(01): 9-15.
[13] 吴小燕, 卢柱标, 陈婷, 余亮, 钟健强, 郭建军. 丁苯酞联合重组组织型纤溶酶原激活剂静脉溶栓治疗对急性缺血性卒中患者预后的影响[J]. 中华脑血管病杂志(电子版), 2022, 16(06): 422-426.
[14] 张晓丽, 韩鑫, 韩坤锜, 李姗姗, 刘相静, 徐东成, 牟磊. 急性脑梗死患者重组组织型纤溶酶原激活剂静脉溶栓预后相关危险因素分析[J]. 中华脑血管病杂志(电子版), 2022, 16(05): 338-341.
[15] 张开, 周娟, 李玲, 王伟峰. 某县级医院急诊卒中绿色通道在急性缺血性脑卒中静脉溶栓治疗中的作用[J]. 中华脑血管病杂志(电子版), 2022, 16(02): 110-114.
阅读次数
全文


摘要